Naltrexone and Cognitive Behavioral Therapy for the Treatment of Alcohol Dependence: Do Sex Differences Exist?
- 11 March 2008
- journal article
- Published by Wiley in Alcohol: Clinical and Experimental Research
- Vol. 32 (5), 771-776
- https://doi.org/10.1111/j.1530-0277.2008.00633.x
Abstract
Background: Sex differences in regards to pharmacotherapy for alcoholism is a topic of concern following publications suggesting naltrexone, one of the longest approved treatments of alcoholism, is not as effective in women as in men. This study was conducted by combining 2 randomized placebo controlled clinical trials utilizing similar methodologies and personnel in which the data was amalgamated to evaluate sex effects in a reasonable sized sample. Methods: A total of 211 alcoholics (57 female and 154 male) were randomized to the naltrexone/cognitive behavorial thearpy (CBT) or placebo/CBT arm of the 2 clinical trials analyzed. Baseline variables were examined for differences between sex and treatment groups via ANOVA for continuous variable or chi‐squared test for categorical variables. All initial outcome analysis was conducted under an intent‐to‐treat analysis plan. Effect sizes for naltrexone over placebo were determined by Cohen’s D (d). Results: The effect size of naltrexone over placebo for the following outcome variables was similar in men and women [% days abstinent (PDA) d = 0.36, % heavy drinking days (PHDD) d = 0.36, and total standard drinks (TSD) d = 0.36]. Only for men were the differences significant secondary to the larger sample size (PDA p = 0.03; PHDD p = 0.03; TSD p = 0.04). There were a few variables (GGT at week‐12 change from baseline to week‐12: men d = 0.36, p = 0.05; women d = 0.20, p = 0.45 and drinks per drinking day: men d = 0.36, p = 0.05; women d = 0.28, p = 0.34) where the naltrexone effect size for men was greater than women. In women, naltrexone tended to increase continuous abstinent days before a first drink (women d = 0.46, p = 0.09 and men d = 0.00, p = 0.44). Conclusions: The effect size of naltrexone over placebo appeared similar in women and men in our hands suggesting the findings of sex differences in naltrexone response might have to do with sample size and/or endpoint drinking variables rather than any inherent pharmacological or biological differences in response.Keywords
This publication has 23 references indexed in Scilit:
- What Role Does Measuring Medication Compliance Play in Evaluating the Efficacy of Naltrexone?Alcohol: Clinical and Experimental Research, 2007
- Targeted Versus Daily Naltrexone: Secondary Analysis of Effects on Average Daily DrinkingAlcohol: Clinical and Experimental Research, 2006
- Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic reviewAddiction, 2004
- Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta‐AnalysisAlcohol: Clinical and Experimental Research, 2001
- GENDER AND PERIPHERAL NEUROPATHY IN CHRONIC ALCOHOLISM: A CLINICAL-ELECTRONEUROGRAPHIC STUDYAlcohol and Alcoholism, 2000
- Do Women Develop Alcoholic Brain Damage More Readily Than Men?Alcohol: Clinical and Experimental Research, 1992
- Telescoping of Alcoholism in Women AlcoholicsInternational Journal of the Addictions, 1989
- Reliability of a Timeline Method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populationsBritish Journal of Addiction, 1988
- Women's Drinking across the Adult Life Course as Compared to Men'sBritish Journal of Addiction, 1987
- Increased Susceptibility to Liver Disease in Relation to Alcohol Consumption in WomenScandinavian Journal of Gastroenterology, 1987